Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Sanofi doses first patient in phase IIb study of SAR-442168 for relapsing MS

May 15, 2019

Alzheimer's candidate PRI-002 completes phase I testing

May 15, 2019

Flotillin-1/2 as a novel target in patients with CNS inflammatory conditions

May 15, 2019

Integrator proteins shown to resist nerve cell regression

May 15, 2019

Inebilizumab demonstrates safety and efficacy in phase III N-MOmentum study

May 15, 2019

Promising topline results announced from phase IIb study of seltorexant in major depressive disorder

May 14, 2019

NB-01 leads to statistically significant improvements in diabetic neuropathic pain

May 14, 2019

Updated data presented from phase Ib/II study of RG-6206 in boys with DMD

May 14, 2019

Flavonoid promotes pleiotropic neuroprotective effects

May 14, 2019

AVXS-201 gene therapy is effective in reducing symptoms in Rett syndrome murine models

May 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...